Nanoparticle Solutions to Cancer
Our Value Proposition
Nanoparticle-based drug delivery systems suffer from poor accumulation in tumors with traditional "active" or "passive" targeting strategies netting a median delivery efficiency of just 0.7% of the injected dose reaching the tumor.
Our solution to this problem is a novel, patented, expansile nanoparticle that employs a unique Materials-Based Targeting strategy to achieve a 50X improvement in delivery efficiency compared to traditional systems. With this improvement, we demonstrate an increase in survival of over 200% compared to clinical standard of care in ovarian cancer and intraperitoneal mesothelioma.
Treatments for ovarian cancer and intraperitoneal mesothelioma represent a market of ~$250M with additional potential markets in pancreatic, colorectal and other gastric cancers of over $750M.
How it Works
Paclitaxel-loaded expansile nanoparticles, or "PTX-eNPs" for short, localize to intraperitoneal tumors with over 95% accuracy. Once inside a tumor, eNPs swell causing the particle to become stuck whereupon the payload (a drug called paclitaxel) is released, killing the cancer cell.